title: Prostate tumor overexpressed-1, in conjunction with human papillomavirus status, predicts outcome in early-stage human laryngeal squamous cell carcinoma.
abstract: In human cancer, molecular markers combined with clinical characteristics are used increasingly to predict prognosis. Prostate tumor overexpressed-1 (PTOV1), first identified in prostate cancer, is a key factor in tumor progression and correlates with unfavorable clinical outcomes. HPV infection status was tested by HPV E6-targeted multiplex real-time PCR and p16 immunohistochemistry (IHC). Real-time PCR and western blotting analyses were used to examine the mRNA and protein expression levels of PTOV1 in eight paired LSCC samples. IHC was performed to assess PTOV1 protein expression in 196 paraffin-embedded, archived LSCC samples. PTOV1 protein and mRNA expression was increased in LSCC tissues compared with adjacent non-cancerous tissue samples. High expression of PTOV1was significantly associated with advanced TNM stage by the χ2 test. Multivariate analysis revealed that PTOV1 and HPV status were independent prognostic indicators of overall survival (OS) and progression-free survival (PFS) (P = 0.001, P = 0.009 for OS, P = 0.005, P = 0.012 for PFS, respectively). Our study provides the first evidence that the combination of PTOV1 expression level and HPV status provides more prognostic information compared with HPV status alone with the significance still exists in the HPV negative subgroup.
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Yang
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Hongzhi
authors.initials: H
authors.lastname: Wang
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: He
authors.affiliation: The Six Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
authors.forename: Haiyang
authors.initials: H
authors.lastname: Chen
authors.affiliation: The First Hospital of Foshan, Foshan, China.
authors.forename: Shaobo
authors.initials: S
authors.lastname: Liang
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Shasha
authors.initials: S
authors.lastname: He
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Shu
authors.initials: S
authors.lastname: Wu
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Libing
authors.initials: L
authors.lastname: Song
authors.affiliation: Sun Yat-Sen University Cancer Center, Guangzhou, China.|State Key Laboratory of Oncology in Southern China, Guangzhou, China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics; D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000235:genetics / Q000473:pathology / Q000821:virology*; D016009:Chi-Square Distribution; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis; D004279:DNA, Viral / Q000235:genetics; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology / Q000821:virology*; D061809:Human Papillomavirus DNA Tests; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D060885:Multiplex Polymerase Chain Reaction; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics; D009367:Neoplasm Staging; D009856:Oncogene Proteins, Viral / Q000032:analysis; D027383:Papillomaviridae / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000235:genetics / Q000473:pathology / Q000821:virology*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012333:RNA, Messenger / Q000235:genetics; D012307:Risk Factors; D000077195:Squamous Cell Carcinoma of Head and Neck; D013997:Time Factors; D016896:Treatment Outcome; D048868:Adaptor Proteins, Signal Transducing
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D004279:DNA, Viral; D009363:Neoplasm Proteins; D009856:Oncogene Proteins, Viral; D012333:RNA, Messenger; C000614131:CDKN2A protein, human; C425183:PTOV1 protein, human; D048868:Adaptor Proteins, Signal Transducing
keywords: HPV; biomarker; laryngeal squamous cell carcinoma; prognosis; prostate tumor overexpressed-1